Exosla Therapeutics is a UK/German pre-clinical biotech company focused on immune-related diseases, including neuroinflammation. It offers a safe and scalable immunotherapy by leveraging the multimodal action of high-performing extracellular vesicles (EVs) from specific monoclonal mesenchymal stem/stromal cell (MSC) lines, which were previously immortalised to supply the full drug life cycle. The scientific and translational efforts are built on over a decade of foundational work by Prof. Bernd Giebel at the University of Duisburg-Essen, a pioneer in the MSC-EV field.

Exosla Therapeutics

Org chart

Teams

Offices